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The  International Myeloma Working Group 
(IMWG) currently recommends fluorescence in 
situ hybridization (FISH) as the standard ap‑
proach to identification of the primary genetic 
event.9 Currently, there is no consensus on the ap‑
propriate FISH ‑positivity cutoff value for defin‑
ing the presence of del(17p), and the minimum 
percentage of del(17p)‑positive cells associated 
IntroductIon Deletion of chromosome 17p 
[del(17p)] is found in 10% of newly diagnosed pa‑
tients with multiple myeloma (MM), with a higher 
prevalence in more advanced disease.1-3 Its pres‑
ence is associated with a poor prognosis and re‑
sistance to chemotherapy.4,5 These patients tend 
to present with relatively frequent extramedul‑
lary and central nervous system involvement.6-8 
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AbstrAct
IntroductIon Deletion of chromosome 17p [del(17p)] in patients with multiple myeloma is associated 
with a poor prognosis. High ‑dose chemotherapy followed by autologous stem cell transplantation (ASCT) 
remains the standard of treatment in this population.
objEctIvEs The aim of the study was to compare the treatment outcomes with high ‑dose chemotherapy 
and ASCT with standard treatment in patients with del(17p).
PAtIEnts And mEthods We collected data from 12 Polish centers between 2011 and 2017. The records 
of 97 patients with p53 deletion were assessed, including 29 individuals treated with ACST and 68 
receiving standard treatment alone.
rEsuLts During the follow ‑up, 45 patients died and the overall survival (OS) for the whole group was 33 
months (range, 1–66 months), with a median progression ‑free survival (PFS) of 13 months (range, 1–46 
months). The prognostic factors of OS in a multivariable analysis were calcium levels at diagnosis within 
the reference range (hazard ratio [HR], 0.24; 95% CI, 0.12–0.48) and at least partial remission achieved 
after the first ‑line treatment (HR, 0.25; 95% CI, 0.12–0.51). Treatment with ASCT was an important factor 
in improving survival (HR, 3.23; 95% CI, 1.52–6.84). Abnormal kidney function at the time of diagnosis 
reduced the PFS (HR, 0.46; 95% CI, 0.22–0.94). When the analysis was limited only to patients who 
could be candidates for ASCT, the survival benefit of the procedure was lost (P = 0.21).
concLusIons Patients with multiple myeloma with del(17p) do not benefit from high ‑dose chemotherapy 
followed by ACST.
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was cyclophosphamide or melphalan, thalido‑
mide, and dexamethasone, and the second ‑line 
treatment was bortezomib, cyclophosphamide 
and thalidomide, and dexamethasone. The latter 
was the first ‑line treatment since 2015. The ini‑
tial treatment was similar in the standard‑che‑
motherapy and ASCT groups: a thalidomide ‑only 
regimen was administered in 42% and 46% of pa‑
tients, respectively; a bortezomib ‑only regimen, 
in 30% and 29%; and a combined bortezomib and 
thalidomide regimen, in 19% and 20%. Abnormal 
kidney function was defined as a creatinine level 
of higher than 2 mg/dl (176 µmol/l), according to 
the Durie–Salmon staging system.13
Prognostic features and treatment response 
were assessed according to the IMWG Uniform 
Response Criteria.14 The characteristics of pa‑
tients undergoing ASCT are presented in tAbLE 2. 
The median time to transplant was 373 days 
(range, 176–1040 days). Posttransplant analy‑
sis was performed on day 100 for patients treat‑
ed with ASCT. Because only 3 patients received 
maintenance therapy, no separate analysis was 
performed in this group.
Ethics approval All patients provided written 
informed consent to participate in the study. 
The approval of the ethics committee was not 
required at the time of the study.
statistical analysis Overall survival (OS) was cal‑
culated from the time of diagnosis to the time 
of death, using the Kaplan–Meyer method. For 
progression ‑free survival (PFS), death or progres‑
sion was considered an event. The Pearson χ2 and 
Fisher tests were used to compare differences be‑
tween categorical variables. The rank ‑sum test was 
used to compare the distribution of continuous 
variables. A Cox proportional hazard regression 
analysis was applied to compare OS and PFS be‑
tween groups to identify risk factors in patients 
who underwent the ASCT and those treated with 
standard chemotherapy only. Factors found to be 
significant at a P level of 0.2 were then included 
in a multivariable analysis. To determine the ef‑
fect of treatment on survival, a proportional haz‑
ards regression analysis was carried out, which 
included the treatment group adjusted for other 
prognostic factors. All P values were 2 sided. Be‑
cause we did not use an accelerated failure time 
model, conclusions about shorter or longer sur‑
vival are indirect. Analyses were performed us‑
ing the Statistica 13.1 software (2016, Dell Inc, 
Tulsa, Oklahoma, United States).
rEsuLts We collected data from 97 patients 
with the p53 deletion, of whom 29 were treat‑
ed with ASCT as part of their initial treatment. 
The remaining 68 patients received standard 
treatment without high ‑dose chemotherapy. Dur‑
ing the follow ‑up, 45 patients died and the OS 
for the total group was 33 months (range, 1–66 
months) with a median PFS of 13 months (range, 
1–46 months; FIGurEs 1 and 2).
with a poor prognosis is unknown.10 Thesignif‑
icance of the p53 mutation in MM is probably 
associated with a poor prognosis but requires 
additional research, and at present, it can be 
used only in the context of clinical trials.3,9 To 
treat patients with high ‑risk cytogenetics, in‑
cluding patients with del(17p), the IMWG rec‑
ommends bortezomib ‑based induction followed 
by high ‑dose therapy with double ASCT and post‑
transplant bortezomib maintenance.9 This rec‑
ommendation is based mostly on the results of 
the HOVON ‑65/GMMG ‑HD4 trial (Dutch ‑Belgian 
Cooperative Trial Group for Hematology Oncolo‑
gy Group ‑65 / German ‑speaking Myeloma Mul‑
ticenter Group ‑HD4).11
The role of high ‑dose chemotherapy followed 
by autologous stem cell transplantation (ASCT) 
remains controversial. The clinical outcome in 
patients treated with novel drugs compared 
with a matched control group without p53 de‑
letion showed significantly worse survival in 
the del(17p) group.12 However, because there are 
limited data from stratified clinical trials, high‑
‑dose chemotherapy followed by double ASCT is 
still recommended as a standard approach in this 
high ‑risk population of patients.9
In this study, we analyzed real ‑world data from 
MM patients with del(17p) treated with or with‑
out ASCT. We aimed to assess the effectiveness of 
high ‑dose chemotherapy with ASCT in the con‑
text of this high ‑risk genetic abnormality.
PAtIEnts And mEthods We collected data 
on patients with confirmed del(17p) on the ba‑
sis of FISH results. Data were obtained from 12 
Polish centers by searching hospital records, in‑
cluding cytogenetic laboratory results, from 2011 
through 2017. The FISH analysis was performed at 
the participating centers from fresh bone marrow 
aspirates using probes containing DNA sequenc‑
es that were specific to the p53 gene and mapped 
to the 17p13.1 region of chromosome 17. A cutoff 
value of 20% of cells was used to confirm FISH 
positivity. Demographic data and information on 
disease characteristics, treatment regimens, and 
clinical endpoints of patients receiving standard 
chemotherapy and those on high‑does chemother‑
apy with ASCT are summarized in tAbLE 1. Initially, 
the standard first ‑line treatment for all patients 
whAt’s nEw?
Autologous stem cell transplantation (ASCT) is a standard of treatment for 
younger patients with multiple myeloma. It is based on administration of high‑
‑dose chemotherapy followed by stem cell support. However, it is known that 
patients with a confirmed deletion of chromosome 17p do not respond to any 
chemotherapy. Therefore, it is unclear why they should respond to chemother‑
apy given in very high doses. In our opinion, misleading information originates 
from studies that included all patients with high ‑risk disease independently of 
underlying genetic abnormalities. Our data obtained by fluorescence in situ 
hybridization confirmed that ASCT does not provide an expected benefit for 
patients, and it can even be potentially harmful.
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stable and progressive disease. Data from 11 pa‑
tients (16%) were missing or were not assessed. 
There were 34 deaths in this group. The median 
OS was 13 months (range, 1–49 months; FIGurE 1), 
and the median PFS was 4 months (range, 1–19 
months; FIGurE 2).
univariable and multivariable analysis A univari‑
able analysis was performed to determine signifi‑
cant prognostic factors. The following factors were 
nonsignificant: age >65 or >70 years, the type of 
heavy and light chain, presence of osteolytic le‑
sions, or the type of first ‑line treatment includ‑
ing thalidomide, bortezomib, or both. The signif‑
icant prognostic factors for OS included normal 
or increased creatinine levels (HR, 0.37; 95% CI, 
0.20–0.68); normal or increased calcium levels 
(HR, 0.3; 95% CI, 0.17–0.55); response to initial 
treatment: progressive disease/stable disease vs 
PR, VGPR, CR, or stringent CR (HR, 0.24; 95% CI, 
0.13–0.47); and initial treatment with or without 
Autologous stem cell transplant In the group re‑
ceiving high ‑dose chemotherapy with ASCT, 22 
patients (93%) responded to the initial standard 
treatment, achieving at least partial remission 
(PR) at the time of transplant (tAbLE 1). Progressive 
disease was noted in only 1 patient, and 1 patient 
progressed from PR to complete remission (CR) 
as a result of the second‑line treatment. During 
the study, 11 deaths were reported. The median 
OS was 42 months (range, 9–68 months; FIGurE 1), 
and the median PFS was 12 months (range, 2–46 
months; FIGurE 2). Six patients underwent double 
transplant (tAbLE 2). There was no difference in OS 
between the single‑ and double ‑transplant group 
(HR, 0.43; 95% CI, 0.17–1.12).
standard-treatment group Among patients who 
achieved CR (9%) at the end of the first ‑line treat‑
ment, very good partial response (VGPR) was not‑
ed in 10 (15%), PR in 18 (27%), and the remain‑
ing 23 patients (34%) were assessed as having 
tAbLE 1 Characteristics of the whole study group, patients receiving standard chemotherapy, and those receiving high ‑dose chemotherapy 
followed by autologous stem cell transplant
Parameter All patients 
(n = 97)
Chemotherapy 
+ ASCT (n = 29)
Standard chemotherapy 
(n = 68)
P value (ASCT vs 
chemotherapy)
Age, y, median (range) 63 (38–84) 59 (38–67) 64.5 (43–84) <0.001
Sex, n (%) Female 42 (43) 14 (48) 28 (41) 0.19
Male 55 (57) 15 (52) 40 (59)
Myeloma subtype, n (%) IgG – 15 (52) 32 (47) 0.27
IgA – 9 (31) 18 (26) –
Light ‑chain only – 3 (10) 16 (24) –
Nonsecretory – 2 (7) 1 (1) –
Light chain type, n (%) Kappa 56 (58) 17 (59) 39 (57) –
Lambda 35 (36) 10 (34) 25 (37) 0.86
Unknown 6 (6) 2 (7) 4 (6) –
Creatinine level 
at diagnosis, n (%)  
Normal 71 (73) 25 (86) 46 (68) 0.06
Increased 26 (27) 4 (14) 22 (32) –
Calcium level 
at diagnosis, n (%)
Normal 67 (63) 20 (69) 47 (69) 0.97
Increased 30 (31) 9 (31) 21 (31) –
Osteolytic lesions, n (%) Yes 88 (91) 62 (91) 26 (90) 0.81
No 9 (9) 6 (9) 3 (10) –
β2‑microglobulin, mg/l,  
median (range)
4.95 (1.2–49.7) 3.9 (1.2–17.8) 9.0 (1.5–49.7) <0.001
ISS, n (%) 1 28 (29) 11 (38) 7 (10) <0.001
2 29 (30) 11 (38) 18 (26) –
3 34 (35) 2 (7) 32 (47) –
Unknown 16 (16) 5 (17) 11 (16) –
Best response to 
the initial treatment, n (%)
sCR 1 (1) 1 (3) – <0.001a
CR 12 (12) 6 (21) 6 (9) –
VGPR 23 (24) 13 (45) 10 (15) –
PR 25 (26) 7 (24) 18 (26) –
SD 3 (3) – 3 (4) –
PD 22 (23) 2 (7) 20 (29) –
a sCR + CR + VGPR + PR vs PD
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; IgA, immunoglobulin A; IgG, immunoglobulin G; PD, progressive 
disease; PR, partial response; sCR, stringent complete response; VGPR, very good partial response
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reported as the best method to identify a high‑
‑risk population.19 However, we did not include 
patients with the TP53 mutation in our study. 
Among patients with del(17p), only 18 had a can‑
cer clonal fraction higher than 0.55. No differ‑
ence was found between the group with a thresh‑
old of >0.2 and that with <0.55 and >0.55, most 
probably due to a very small population.
Chang et al20 did not confirm the effective‑
ness of ASCT in genetic high ‑risk groups, includ‑
ing individuals with del(17p). The IFM 2005–01 
trial, which compared bortezomib plus dexa‑
methasone versus vincristine, doxorubicin, and 
dexamethasone followed by auto ‑ASCT, failed 
to confirm the benefit of the new treatment in 
a subgroup of patients with del(17p).21 However, 
the current IMWG recommendation for the treat‑
ment of patients with high ‑risk cytogenetics, 
including patients with del(17p), is a prolonged 
bortezomib ‑based treatment followed by high‑
‑dose therapy with double ASCT.11 This is based 
mostly on the results of the randomized phase 
III HOVON ‑65/GMMG ‑HD4 study, which as‑
signed newly diagnosed symptomatic patients 
with MM to receive induction therapy with vin‑
cristine, doxorubicin, and dexamethasone or bort‑
ezomib, doxorubicin, and dexamethasone fol‑
lowed by high ‑dose melphalan and ASCT main‑
tenance consisting of thalidomide or bortezomib 
for 2 years. A significant advantage of bortezomib‑
‑based treatment was observed in patients with 
the 17p13 deletion (median PFS, 12 months vs 22 
months; median OS, 24 months vs not reached 
at 54 months; HR, 0.36; 95% CI, 0.18 to 0.74). 
In a study by Shaughnessy et al,22 441 patients 
were treated with Total Therapy 3, which incor‑
porated bortezomib, thalidomide, and dexameth‑
asone induction followed by consolidation and 
maintenance treatment. In contrast to the pre‑
vious Total Therapy 2, Total Therapy 3 results did 
not show any negative effect on the rate or dura‑
tion of the CR or survival associated with the pres‑
ence of p53 haploinsufficiency.22 The benefit of 
bortezomib, thalidomide, and dexamethasone 
followed by double ASCT in this high ‑risk group 
was also observed in the GIMEMA study (Italian 
Group for Hematological Disease in Adults).23 
A recent meta ‑analysis by Liu et al24 suggested 
an improved survival of patients with del(17p) if 
they were treated with a combination of carfilzo‑
mib or elotuzumab and lenalidomide or pomalid‑
omide with dexamethasone followed by bortezo‑
mib maintenance.
The  recommendation for double ASCT is 
based on a  meta ‑analysis of 4 European tri‑
als.25 These studies include high ‑risk patient 
groups with del(17p) but also with transloca‑
tion  t(4; 14). The  4 ‑year OS rate was 76% in 
the tandem ‑transplant group and 33% in patients 
who received only a single procedure. However, 
the advantage of tandem transplant in MM was 
not confirmed in prospective studies. In the Bo‑
logna 96 study, Cavo et al26 observed higher CR 
rates after double ASCT (47% vs 33%, P <0.01) in 
ASCT (HR, 3.22; 95% CI, 1.52–6.82). Only 1 fac‑
tor (abnormal kidney function at diagnosis) was 
significant for PFS (HR, 0.46; 95% CI, 0.22–0.94).
The following 3 factors remained significant 
for OS in the multivariable analysis: no increase 
in the calcium level at diagnosis (HR, 0.24; 95% 
CI, 0.12–0.48); minimum PR achieved as a re‑
sult of the first ‑line treatment (HR, 0.25; 95% 
CI, 0.12–0.51); and worse prognosis seen in pa‑
tients without ASCT as part of the initial treat‑
ment (HR, 3.22; 95% CI, 1.52–6.83).
Next, we investigated whether patients benefit‑
ed from high ‑dose chemotherapy, so only poten‑
tial candidates for ASCT were included in the anal‑
ysis. When the comparison was limited only to 
patients who obtained at least PR as a result of 
the initial treatment and were 70 years old or 
younger, a survival benefit in transplant recipi‑
ents was no longer observed (P = 0.21).
dIscussIon Despite considerable progress in 
the treatment of MM, adverse genetic risk con‑
tinues to have a significant impact on survival. 
This applies particularly to patients with del(17p). 
However, the first question is how del(17p) should 
be defined. The cutoff values up to 60% from a sin‑
gle cell were accepted in different studies.15,16 Also, 
the cutoff value related to the FISH positivity has 
been recently discussed in detail.17 However, there 
is no consensus on the appropriate cutoff value 
for defining the presence of del(17p). In our study, 
the cutoff of 20% was set based on standard cri‑
teria that were in use during the study period. 
Additionally, the optimal management of this 
group of patients remains controversial.18 Recent‑
ly, the cancer clonal fraction threshold of 0.55 for 
patients with the TP53 mutation or deletion was 
tAbLE 2 Characteristics of autologous stem cell transplantation
Parameter Value
Transplant Single 22 (76)
Tandem 7 (24)
Conditioning regimen (first 
transplant)
MEL200 24 (83)
MEL140 5 (17)
Results of the first transplant sCR 1 (3)
CR 7 (24)
VGPR 12 (41)
PR 7 (24)
PD 1 (3)
Missing/not 
assessed
1 (3)
Conditioning regimen (second 
transplant)
MEL200 6 (71.4)
Other 2 (28.6)
Results of the second transplant CR 4 (50)
VGPR 2 (25)
PR 2 (25)
Data are presented as number (percentage) of patients.
Abbreviations: MEL140, melphalan 140 mg/m2 of body surface; MEL200, melphalan 
200 mg/m2 of body surface; others, see tAbLE 1
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was found in patients who were initially treated 
with proteasome inhibitors or immunomodula‑
tory drugs.12
Our study confirmed the poor prognosis in 
patients with del(17p). Similar to some other 
studies, our results did not corroborate previous 
findings on significant effectiveness of high ‑dose 
high ‑risk groups, but failed to show prolonged OS. 
There has been no prospective studies on the ef‑
fectiveness of ASCT limited only to patients with 
del(17p13). In a case ‑matched study where patients 
with del(17p) were compared with standard ‑risk 
patients from the University of Texas MD Ander‑
son Cancer Center database, no benefit of ASCT 
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FIGurE 1  Overall 
survival in patients 
treated with standard 
chemotherapy and high‑
‑dose chemotherapy with 
autologous stem cell 
transplantation (ASCT)
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FIGurE 2 Progression‑
‑free survival in patients 
treated with standard 
chemotherapy and high‑
‑dose chemotherapy with 
autologous stem cell 
transplantation (ASCT)
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treatment compared with standard therapy based 
on novel drugs. In a multicenter analysis from 8 
centers in Israel, Cohen et al27 noted improved 
survival after ASCT only in patients who were in 
remission for a minimum of 6 months. Kroger 
et al28 showed that only the use of a combined 
tandem autologous –allogeneic transplantation 
can overcome the negative prognostic effect of 
del(17p13) in patients with complete molecu‑
lar remission.
Apart from ASCT as part of treatment as well 
as response to the initial treatment, hypercalce‑
mia was found to remain significant. This obser‑
vation has been recently confirmed by Zagouri 
et al.29 Additionally, there are extensive litera‑
ture data on kidney failure as a risk factor for 
MM and ASCT.30-33
Our study confirms that ASCT has no benefit 
in MM. However, because of the limitation relat‑
ed to the retrospective design, this issue should 
be addressed in future prospective (possibly ran‑
domized) studies.
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